Literature DB >> 16565845

The role of FDG-PET/CT in the detection of recurrent colorectal cancer.

Jana Votrubova1, Otakar Belohlavek, Monika Jaruskova, Martin Oliverius, Radka Lohynska, Kristina Trskova, Eva Sedlackova, Ludmila Lipska, Vladimira Stahalova.   

Abstract

PURPOSE: The conventional diagnostic techniques used to assess recurrence of colorectal cancer (CRCR) often yield unspecific findings. Integrated FDG-PET/CT seems to offer promise for the differential diagnosis of benign and malignant lesions. The aim of this study was to compare the value of FDG-PET and PET/CT in the detection of CRCR subsequent to colonic resection or rectal amputation.
METHODS: The population for this retrospective study comprised 84 patients with suspected CRCR. The sensitivity, specificity and accuracy of PET and PET/CT were calculated for (a) intra-abdominal extrahepatic recurrences, (b) extra-abdominal and/or hepatic recurrences and (c) all recurrences, and tumour marker levels were analysed.
RESULTS: The sensitivity, specificity and overall accuracy of PET in detecting intra-abdominal extrahepatic CRCR were 82%, 88% and 86%, respectively, compared with 88%, 94% and 92%, respectively, for PET/CT. The corresponding figures for detection of extra-abdominal and/or hepatic CRCR were 74%, 88% and 85% for PET and 95%, 100% and 99% for PET/CT. Considering the entire population, the sensitivity, specificity and overall accuracy of PET were 80%, 69% and 75%, respectively, compared with 89%, 92% and 90%, respectively, for PET/CT. FDG-PET/CT examination correctly detected 40 out of a total of 45 patients with CRCR. Two of five patients with falsely negative FDG-PET/CT findings had local microscopic recurrences and one had miliary liver metastases. Of 39 patients without CRCR, three showed false positive FDG-PET/CT results. Two of these cases were due to increased accumulation in inflammatory foci in the bowel wall, while one was due to haemorrhaging into the adrenal gland.
CONCLUSION: FDG-PET/CT appears to be a very promising method for distinguishing a viable tumour from fibrous changes, thereby avoiding unnecessary laparotomy.

Entities:  

Mesh:

Year:  2006        PMID: 16565845     DOI: 10.1007/s00259-006-0072-z

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  16 in total

1.  Preoperative assessment of local tumor extent in advanced rectal cancer: CT or high-resolution MRI?

Authors:  R G Beets-Tan; G L Beets; A C Borstlap; T K Oei; T M Teune; M F von Meyenfeldt; J M van Engelshoven
Journal:  Abdom Imaging       Date:  2000 Sep-Oct

2.  Staging recurrent metastatic colorectal carcinoma with PET.

Authors:  D Delbeke; J V Vitola; M P Sandler; R C Arildsen; T A Powers; J K Wright; W C Chapman; C W Pinson
Journal:  J Nucl Med       Date:  1997-08       Impact factor: 10.057

3.  The pelvis after surgery and radio-chemotherapy for rectal cancer studied with Gd-DTPA-enhanced fast dynamic MR imaging.

Authors:  L Blomqvist; P Fransson; T Hindmarsh
Journal:  Eur Radiol       Date:  1998       Impact factor: 5.315

4.  Comparison between 18F-FDG PET, in-line PET/CT, and software fusion for restaging of recurrent colorectal cancer.

Authors:  Jong-Ho Kim; Johannes Czernin; Martin S Allen-Auerbach; Benjamin S Halpern; Barbara J Fueger; Joel R Hecht; Osman Ratib; Michael E Phelps; Wolfgang A Weber
Journal:  J Nucl Med       Date:  2005-04       Impact factor: 10.057

5.  Additional value of whole-body positron emission tomography with fluorine-18-2-fluoro-2-deoxy-D-glucose in recurrent colorectal cancer.

Authors:  P Flamen; S Stroobants; E Van Cutsem; P Dupont; G Bormans; N De Vadder; F Penninckx; L Van Hoe; L Mortelmans
Journal:  J Clin Oncol       Date:  1999-03       Impact factor: 44.544

6.  Accuracy of whole-body dual-modality fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography (FDG-PET/CT) for tumor staging in solid tumors: comparison with CT and PET.

Authors:  Gerald Antoch; Nina Saoudi; Hilmar Kuehl; Gerlinde Dahmen; Stefan P Mueller; Thomas Beyer; Andreas Bockisch; Jörg F Debatin; Lutz S Freudenberg
Journal:  J Clin Oncol       Date:  2004-11-01       Impact factor: 44.544

Review 7.  PET imaging in assessing gastrointestinal tumors.

Authors:  Roland Hustinx
Journal:  Radiol Clin North Am       Date:  2004-11       Impact factor: 2.303

Review 8.  Rectal cancer: review with emphasis on MR imaging.

Authors:  Regina G H Beets-Tan; Geerard L Beets
Journal:  Radiology       Date:  2004-08       Impact factor: 11.105

9.  Routine (18)F-FDG PET preoperative staging of colorectal cancer: comparison with conventional staging and its impact on treatment decision making.

Authors:  Iva Kantorová; Ludmila Lipská; Otakar Bêlohlávek; Vladimír Visokai; Miroslav Trubaĉ; Michaela Schneiderová
Journal:  J Nucl Med       Date:  2003-11       Impact factor: 10.057

10.  Incremental value of CT in PET/CT of patients with colorectal carcinoma.

Authors:  I R Kamel; C Cohade; E Neyman; E K Fishman; R L Wahl
Journal:  Abdom Imaging       Date:  2004-05-27
View more
  26 in total

Review 1.  Positron emission tomography for benign and malignant disease.

Authors:  Anthony Visioni; Julian Kim
Journal:  Surg Clin North Am       Date:  2011-02       Impact factor: 2.741

Review 2.  Metabolic positron emission tomography imaging in cancer detection and therapy response.

Authors:  Aizhi Zhu; Daniel Lee; Hyunsuk Shim
Journal:  Semin Oncol       Date:  2011-02       Impact factor: 4.929

3.  Diagnostic performance of MDCT, PET/CT and gadoxetic acid (Primovist(®))-enhanced MRI in patients with colorectal liver metastases being considered for hepatic resection: initial experience in a single centre.

Authors:  V O Chan; J P Das; J F Gerstenmaier; J Geoghegan; R G Gibney; C D Collins; S J Skehan; D E Malone
Journal:  Ir J Med Sci       Date:  2012-03-17       Impact factor: 1.568

4.  Selection for hepatic resection of colorectal liver metastases: expert consensus statement.

Authors:  Reid B Adams; Thomas A Aloia; Evelyne Loyer; Timothy M Pawlik; Bachir Taouli; Jean-Nicolas Vauthey
Journal:  HPB (Oxford)       Date:  2013-02       Impact factor: 3.647

5.  Value of Surveillance (18)F-FDG PET/CT in Colorectal Cancer: Comparison with Conventional Imaging Studies.

Authors:  Eun Kyoung Choi; Ie Ryung Yoo; Hye Lim Park; Hyun Su Choi; Eun Ji Han; Sung Hoon Kim; Soo Kyo Chung; Joo Hyun O
Journal:  Nucl Med Mol Imaging       Date:  2012-06-16

Review 6.  18F-FDG uptake in lung, breast, and colon cancers: molecular biology correlates and disease characterization.

Authors:  Hossein Jadvar; Abass Alavi; Sanjiv S Gambhir
Journal:  J Nucl Med       Date:  2009-10-16       Impact factor: 10.057

7.  Detection of resectable recurrences in colorectal cancer patients with 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography.

Authors:  Nan-Jing Peng; Chin Hu; Tai-Ming King; Yu-Li Chiu; Jui-Ho Wang; Ren-Shyan Liu
Journal:  Cancer Biother Radiopharm       Date:  2013-05-28       Impact factor: 3.099

8.  Performance of integrated FDG PET/contrast-enhanced CT in the diagnosis of recurrent colorectal cancer: Comparison with integrated FDG PET/non-contrast-enhanced CT and enhanced CT.

Authors:  Kazuhiro Kitajima; Koji Murakami; Erena Yamasaki; Yasushi Domeki; Masahiro Tsubaki; Masakatsu Sunagawa; Yasushi Kaji; Narufumi Suganuma; Kazuro Sugimura
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-04-16       Impact factor: 9.236

9.  Non-enhanced CT versus contrast-enhanced CT in integrated PET/CT studies for nodal staging of rectal cancer.

Authors:  Ukihide Tateishi; Tetsuo Maeda; Tsuyoshi Morimoto; Mototaka Miyake; Yasuaki Arai; E Edmund Kim
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-05-26       Impact factor: 9.236

Review 10.  PET/CT in oncology: for which tumours is it the reference standard?

Authors:  Conor D Collins
Journal:  Cancer Imaging       Date:  2007-10-01       Impact factor: 3.909

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.